Related Experiment Video
Updated: Jun 4, 2025
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.2K
Clinically approved representative small-molecule drugs for cardiopathy therapy
Shaowei Ma1, Min Jiang2, Xiao Wang3
1Department of Interventional Therapy, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China; Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
European Journal of Medicinal Chemistry
|December 20, 2024
Summary
Small-molecule drugs significantly improve cardiovascular disease outcomes but face challenges like resistance and toxicity. This review details current treatments and future cardioprotective agent development for better cardiopathy management.
Area of Science:
- Pharmacology and Cardiology
- Drug Discovery and Development
Background:
- Therapeutic agents, particularly small-molecule drugs, have advanced cardiovascular disease (CVD) treatment, reducing morbidity, mortality, and healthcare costs.
- Current treatments for cardiopathy show variable efficacy, face drug resistance, and can cause toxicities, complicating long-term patient management.
Purpose of the Study:
- To review clinically approved small-molecule drugs used in cardiopathy treatment.
- To analyze the synthetic routes, mechanisms of action, and therapeutic roles of these agents.
- To provide perspectives on developing next-generation cardioprotective agents for optimized CVD management.
Main Methods:
- Comprehensive literature review of small-molecule drugs for cardiopathy.
- Analysis of major drug classes: angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, and SGLT2 inhibitors.
- Examination of synthetic pathways, pharmacological actions, and clinical applications.
Main Results:
- Detailed overview of established small-molecule drug classes and their impact on cardiopathy.
- Identification of limitations including patient response variability, drug resistance, and adverse effects.
- Synthesis of current therapeutic strategies and their associated challenges.
Conclusions:
- Small-molecule drugs are crucial in managing cardiopathy, but challenges necessitate further research.
- Future development should focus on novel cardioprotective agents to overcome existing limitations and improve patient outcomes.
- Optimizing therapeutic strategies requires a deeper understanding of drug mechanisms and resistance pathways.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
01:26Heart Failure Drugs: Inotropic Agents
516
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
453
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
453
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
01:22Heart Failure Drugs: β-Blockers
315
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140